Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of amrubicin vs carboplatin plus etoposide in elderly extensive-disease SCLC
jRCT1080220200Phase 3
- Sponsor
- Sumitomo Pharma
- Start
- Jan 2006
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of amrubicin in small cell lung cancer (SCLC) (2 arms), sponsored by Sumitomo Pharma.
02
Drugs
amrubicin
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on jRCT1080220200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1080220200.